Why your blood can turn against you: the mystery of thrombotic thrombocytopenic purpura
In short: Thrombotic thrombocytopenic purpura is a life-threatening blood disorder where clots form spontaneously in small vessels. It is driven by a deficiency in a critical enzyme, ADAMTS13, which normally prevents runaway clotting. Without this regulator, the body consumes its own platelets, leading to dangerous blockages and potential organ failure.
The core of the condition lies in the ADAMTS13 enzyme, which acts as a molecular pair of scissors. Its job is to break down von Willebrand factor, a protein that helps platelets stick together. When ADAMTS13 is missing or inhibited, these factors grow into massive, sticky chains that trigger clotting in the microvasculature. As platelets are rapidly consumed to build these unnecessary clots, the body loses its ability to stop bleeding elsewhere, creating a paradoxical state of both clotting and potential hemorrhage.
Most cases are acquired, meaning the immune system mistakenly produces antibodies that attack the ADAMTS13 enzyme. This autoimmune response can be triggered by various factors, including infections, pregnancy, or certain medications. A smaller subset of cases is congenital, known as Upshaw–Schulman syndrome, where a genetic mutation prevents the body from producing sufficient ADAMTS13 from birth. While historically fatal, the introduction of therapeutic plasma exchange—which replaces the missing enzyme and removes the harmful antibodies—has drastically improved survival rates.
Modern treatment is multifaceted. Beyond plasma exchange, clinicians use immunosuppressants like rituximab or corticosteroids to stop the immune system from attacking the enzyme. Newer targeted therapies, such as caplacizumab, prevent platelets from aggregating, while genetically engineered ADAMTS13 proteins like adzynma offer a precise way to restore balance in congenital cases. Despite these advancements, the condition remains a medical emergency, often presenting with subtle symptoms like fatigue or headaches before escalating into severe neurological or cardiac dysfunction.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Thrombotic Thrombocytopenic Purpura (TTP)
- Also: What Is Thrombotic Thrombocytopenic Purpura (TTP)?
- Also: Thrombotic thrombocytopenic purpura
To cite this card, link to https://intellectplus.co.uk/app/technology-thrombotic-thrombocytopenic-purpura.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Health · Latest · A–Z · All topics